Teva Cost-Structure Sustainable After Generic Price Drop, CEO Says

The transcript discusses Teva's strategic focus on cost restructuring and growth through new generics and innovative treatments. It covers financial forecasts, market challenges, and the impact of US politics on drug pricing. The status of opioid lawsuits and potential settlements is addressed, along with the effects of the coronavirus on the API supply chain. The EpiPen market, including supply and pricing pressures, is also discussed.

In what ways is Teva innovating beyond generics, as highlighted in the text?

What factors contributed to the stabilization of pricing in the generic drug market?

What is Teva's position on the EpiPen market, and how has their pricing strategy evolved?